Ishida Ryo, Yamada Natsuki, Sato Kana, Maekawa Ayako, Kamei Takehito, Akagi Shinsuke, Tokuda Hidenori, Tokumasu Hironobu, Mizuno Motowo, Takayanagi Kazunobu
Clinical Research Center, Kurashiki Central Hospital, Miwa1-1-1, Kurashiki-city, Okayama, 710-8602, Japan.
Division of Pharmacy, Kurashiki Central Hospital, Miwa1-1-1, Kurashiki-city, Okayama, 710-8602, Japan.
J Pharm Health Care Sci. 2025 Jun 18;11(1):51. doi: 10.1186/s40780-025-00459-w.
Pharmacy formulary systems have been established recently in various fields of pharmacotherapies. We evaluated the effectiveness of pharmacy formulary interventions on proton pump inhibitors (PPI) used to prevent drug-induced peptic ulcers in a Japanese tertiary hospital.
A retrospective cohort study was conducted in Kurashiki Central Hospital. A pharmacy formulary system of PPIs was implemented on October 1, 2020. Between April 2020 and March 2021, six months before and after the implementation date of the formulary system, inpatients aged ≥ 18 years were included if they newly received drugs (low-dose aspirin, anti-platelets, or non-steroidal anti-inflammatory drugs) recommended for prophylactic PPI use for peptic ulcers within seven days from hospital admission. Eligible patients were divided into two groups based on the implementation date, and changes in PPI prescription patterns were evaluated by interrupted time series analysis, along with the risk of drug-induced peptic ulcers and drug costs.
In total, 2,449 inpatients were included. The median age of the pre- and post-formulary group was 60 and 58 years, respectively. The proportion of the targeted PPI prescription increased by 8.75% (95% confidence interval (CI); 0.12, 17.38) in level change, without increased risk of drug-induced peptic ulcers (risk difference -0.41%, 95% CI; -1.38, 0.55). The distribution of medication days in the two groups was similar, and $1,000 per 90 patient days was saved on drug costs.
The formulary system on oral PPIs in a Japanese tertiary hospital contributed to a positive level change in the prescription patterns, without increased risk of drug-induced peptic ulcers. Although slight, the drug costs were saved.
药学处方集系统最近已在各种药物治疗领域中建立。我们评估了药学处方集干预措施对日本一家三级医院中用于预防药物性消化性溃疡的质子泵抑制剂(PPI)的有效性。
在仓敷中央医院进行了一项回顾性队列研究。2020年10月1日实施了PPI的药学处方集系统。在2020年4月至2021年3月期间,即处方集系统实施日期前后的六个月,年龄≥18岁的住院患者如果在入院后七天内新接受了推荐用于预防性使用PPI治疗消化性溃疡的药物(低剂量阿司匹林、抗血小板药物或非甾体抗炎药),则纳入研究。符合条件的患者根据实施日期分为两组,并通过中断时间序列分析评估PPI处方模式的变化,以及药物性消化性溃疡的风险和药物成本。
总共纳入了2449名住院患者。处方集实施前和实施后组的中位年龄分别为60岁和58岁。目标PPI处方比例在水平变化上增加了8.75%(95%置信区间(CI);0.12,17.38),而药物性消化性溃疡的风险没有增加(风险差异-0.41%,95%CI;-1.38,0.55)。两组的用药天数分布相似,每90个患者日节省了1000美元的药物成本。
日本一家三级医院的口服PPI处方集系统有助于处方模式的正向水平变化,且药物性消化性溃疡的风险没有增加。虽然节省的药物成本不多,但仍有节省。